The American Society of Hematology (ASH) has added to its eLearning platform a new educational course titled “Biosimilars: A New Era of Hematology/Oncology Management Considerations”.
A synopsis provided by AHS:
“With the increasing entry of biosimilars into clinical practice it is important to equip and prepare hematology/oncology clinicians with information that can provide a context for the appropriate use of biosimilars. This program looks to increase clinician awareness, knowledge, and confidence regarding the role of biosimilars in clinical care, which has the potential for a notably positive impact on patient access to biologic therapy, as well as cost of care.”
Targeted to “hematologists, hematologist/oncologists, oncologists, and others who are managing patients with neoplasms and need to stay updated on developments related to biosimilars,” the resource provides a “two-part, audio-guided online course [that] presents practical, foundational information on biosimilars, while also addressing issues and barriers most commonly encountered in the clinical setting.”
Learn more and utilize this new educational course about biosimilars from AHS.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.